Brian J. Lynch - 04 Dec 2023 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role: SVP and General Counsel
Signature: /s/ Brian J. Lynch
Issuer symbol: MDGL
Transactions as of: 04 Dec 2023
Net transactions value: -$388,114
Form type: 4
Filing time: 06 Dec 2023, 16:30:08 UTC
Previous filing: 01 Dec 2023
Next filing: 18 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MDGL	Common Stock	Options Exercise	$59,000	+800	+5.3%	$73.75	15,801	04 Dec 2023	Direct	F1
transaction	MDGL	Common Stock	Options Exercise	$87,090	+1,000	+6.3%	$87.09	16,801	04 Dec 2023	Direct	F2
transaction	MDGL	Common Stock	Sale	$172,584	-800	-4.8%	$215.73	16,001	04 Dec 2023	Direct
transaction	MDGL	Common Stock	Sale	$221,380	-1,000	-6.2%	$221.38	15,001	04 Dec 2023	Direct
transaction	MDGL	Common Stock	Options Exercise	$87,090	+1,000	+6.7%	$87.09	16,001	05 Dec 2023	Direct	F2
transaction	MDGL	Common Stock	Sale	$227,330	-1,000	-6.2%	$227.33	15,001	05 Dec 2023	Direct
holding	MDGL	Common Stock						530	04 Dec 2023	In IRA

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MDGL	Stock Option (Right to Buy)	Options Exercise	$0	-800	-3.8%	$0.000000	20,200	04 Dec 2023	Common Stock	1,000	$73.75	Direct	F1
transaction	MDGL	Stock Option (Right to Buy)	Options Exercise	$0	-1,000	-2.2%	$0.000000	44,000	04 Dec 2023	Common Stock	1,000	$87.09	Direct	F2
transaction	MDGL	Stock Option (Right to Buy)	Options Exercise	$0	-1,000	-2.3%	$0.000000	43,000	05 Dec 2023	Common Stock	800	$87.09	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	All shares issued pursuant to the exercise of this option represent 800 shares underlying an overall option award of 25,000 shares. All exercised options had vested. As to the overall option for 25,000 shares, 25% of the shares underlying the option vested on August 10, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.
F2	All shares issued pursuant to the exercise of this option represent 2,000 shares underlying an overall option award of 45,000 shares. All exercised options had vested. As to the overall option for 45,000 shares, 25% of the shares underlying the option vested on February 22, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

Content

All shares issued pursuant to the exercise of this option represent 800 shares underlying an overall option award of 25,000 shares. All exercised options had vested. As to the overall option for 25,000 shares, 25% of the shares underlying the option vested on August 10, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

All shares issued pursuant to the exercise of this option represent 2,000 shares underlying an overall option award of 45,000 shares. All exercised options had vested. As to the overall option for 45,000 shares, 25% of the shares underlying the option vested on February 22, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.